TARS News and Press, Tarsus Pharmaceuticals Inc. From 09/07/22

Tarsus Pharmaceuticals ( NASDAQ: TARS ) submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of TP-03 to treat Demodex blepharitis. Demodex blepharitis is inflammation of the eyelids caused by a type o...

IRVINE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has submitted a New D...

Tarsus Pharmaceuticals press release ( NASDAQ: TARS ): Q2 GAAP EPS of -$0.24 beats by $0.48 . Revenue of $15.28M (-30.6% Y/Y) beats by $4.03M . For further details see: Tarsus Pharmaceuticals GAAP EPS of -$0.24 beats by $0.48, revenue of $15.28M beats by ...

TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; NDA submission expected this year Initiated Ersa Phase 2a trial evaluating TP-03 for the treatment of Meibomian Gland Disease Cash runway anticipated into at least 2026 for th...

IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has enrolled the first...

PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022. Her appointment brings the company’s board of directors to eleven m...

IRVINE, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D....

Tarsus Pharmaceuticals press release (NASDAQ:TARS): Q1 GAAP EPS of -$0.98 misses by $0.06. Revenue of $0.54M (-98.4% Y/Y) Cash runway expected into at least 2026: $175 million of cash as of March 31, 2022, and $71 million net follow-on equity raise completed in May 2022 For further det...

TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; anticipated NDA submission in the second half of this year Cash runway expected into at least 2026 IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. ...

IRVINE, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D....